Shield Therapeutics plc
STX.LSeagate Technology Holdings plc is an American data storage company. It was incorporated in 1978 as Shugart Technology and commenced business in 1979. Since 2010, the company has been incorporated in Dublin, Ireland, with operational headquarters in Fremont, California, United States.
Drugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Ferrous sulfate
Anemia
Ferric Carboxy Maltose
Anemia, Iron-Deficiency
ST10
Iron Deficiency Anaemia
ST10-021
Iron Deficiency Anaemia
Ferric maltol
Renal Insufficiency, Chronic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ferrous sulfate | Phase 3 | Anemia | - | - |
Ferric Carboxy Maltose | Phase 3 | Anemia, Iron-Deficiency | - | - |
ST10 | Phase 3 | Iron Deficiency Anaemia | - | - |
ST10-021 | Phase 3 | Iron Deficiency Anaemia | - | - |
Ferric maltol | Phase 3 | Renal Insufficiency, Chronic | - | - |
Frequently asked questions
What is in Shield Therapeutics plc's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Shield Therapeutics plc's (STX.L) pipeline across Phase 3. Its lead program is Ferrous sulfate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Shield Therapeutics plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Shield Therapeutics plc (STX.L) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track STX.L biotech catalysts?→
Add STX.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Shield Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.